(Molecular) Pathways, Pathways, and More Pathways

Andrew L. Pecora, MD
Published: Tuesday, Apr 02, 2013
Andrew Pecora, MD

Andrew L. Pecora, MD

Editor-in-Chief
Oncology & Biotech News

Chief Innovations Officer, Professor, and Vice President
of Cancer Services

John Theurer Cancer Center
at Hackensack University
Medical Center

It will soon be a requirement that every practicing oncologist and hematologist has readily available the oncology molecular pathway equivalent of the New York City underground subway map to guide them on “which train to take” to get to their patients’ desired destination. The content of the 2013 Gastrointestinal (GI) and Genitourinary (GU) Cancers Symposia further illustrates that the oncology we all learned over the past three decades will soon be a thing of the past, making way for therapy decisions based on what molecular switches should be turned on and off, and of equal importance, in what sequence.

Note: The 2013 Gastrointestinal and Genitourinary Cancers Symposia abstracts discussed in this column can be accessed at http://bit.ly/ascoabstracts.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Publication Bottom Border
Border Publication
x